Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Migaldendranib (MGB)
  • News
  • Resources
  • Careers
  • Contact
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Migaldendranib (MGB)
  • News
  • Resources
  • Careers
  • Contact

Month: October 2020

Ashvattha Therapeutics Announces Formation of Scientific Advisory Board

November 12, 2020October 29, 2020 by ashvatthaadmin

Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.

Categories Press Release

Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020

November 12, 2020October 27, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.

Categories Press Release

Ashvattha Therapeutics Presents Preclinical Data at the American Society of Nephrology (ASN) Virtual Kidney Week 2020

November 12, 2020October 22, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020.

Categories Press Release

Ashvattha Therapeutics Appoints Industry Veteran George G. Montgomery to its Board of Directors

November 12, 2020October 7, 2020 by ashvatthaadmin

Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors.

Categories Press Release

Recent Posts

  • Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
  • Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
  • Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
  • Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
  • Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences

Recent Comments

    Archives

    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • June 2024
    • May 2024
    • February 2024
    • January 2024
    • November 2023
    • October 2023
    • August 2023
    • May 2023
    • April 2023
    • February 2023
    • January 2023
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2025 Ashvattha Therapeutics.
    • Privacy Policy
    © 2025 Ashvattha Therapeutics • Built with GeneratePress